Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Haemonetics Corporation for the three-month period ended June 29, 1996. The company is incorporated in Massachusetts and operates in the medical technology sector, specifically focusing on blood management and plasma processing. As of the reporting date, there were 28,941,580 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 1996 | Q2 1995 |
|---|---|---|
| Net Revenues | $75,506,000 | $68,775,000 |
| Gross Profit | $42,316,000 | $37,317,000 |
| Gross Margin | 56.0% | 54.3% |
| Operating Income | $14,147,000 | $13,560,000 |
| Net Income | $9,422,000 | $8,740,000 |
| Diluted EPS | $0.34 | $0.32 |
| Cash from Operations | ($1,368,000) | $7,172,000 |
| Total Debt | $19,196,000 | $34,396,000 (Year Ago) |
| Working Capital | $115,844,000 | N/A |
Liquidity: Cash and short-term investments stood at $10.9 million. The company reported a working capital increase to $115.8 million.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 9.8% year-over-year. International sales grew 21%, offset by a 12% decline in the domestic market.
- Margin Expansion: Gross margin improved by 1.7 percentage points, driven by a higher mix of international sales and favorable currency impacts.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose to $23.1 million (30.6% of revenue) from $19.5 million (28.2% of revenue) due to increased staffing costs. R&D expenses increased to $5.0 million.
- Cash Flow Reversal: Operating cash flow turned negative at ($1.4) million, compared to a positive $7.2 million in the prior year. This was driven by increases in accounts receivable ($5.3 million), inventory ($2.1 million), and sales-type leases ($3.6 million).
- Debt Reduction: Total debt decreased significantly by $15.2 million compared to the same period a year ago, though it increased slightly ($0.7 million) from the previous quarter.
Outlook, Risks, and Management Commentary
- Liquidity Strategy: Management believes committed bank lines and internally generated funds are sufficient to meet future needs. The company utilized $1.4 million from revolving credit agreements during the quarter.
- Capital Expenditures: Net cash used for capital expenditures was $4.2 million, primarily for equipment in the U.S. commercial plasma business and facility investments.
- Foreign Exchange: The company holds forward exchange contracts totaling $120.7 million to hedge foreign currency risk. Gross unrealized gains on these hedges were $4.3 million.
- Management Change: Effective May 3, 1996, Brigid A. Makes was named Chief Financial Officer, replacing Neal Armstrong.
- Tax Rate: The provision for income taxes remained at approximately 35% of pretax income, with an expected annualized rate of 35% for fiscal 1997.
Investor Verification Checklist
- Verify the sustainability of the 21% international sales growth versus the 12% domestic decline.
- Monitor the trend of operating cash flow, which turned negative due to working capital build-up (receivables and inventory).
- Assess the impact of the new CFO and any potential shifts in financial strategy.
- Review the $4.2 million capital expenditure plan for the commercial plasma business to ensure ROI aligns with projections.
- Confirm the status of the $120.7 million in foreign currency hedges and their effect on future earnings volatility.